uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Involvement of platelet-derived growth factor in disease: development of specific antagonists
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, Ludwig Institute for Cancer Research.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, Ludwig Institute for Cancer Research.
2001 (English)In: Advances in Cancer Research, ISSN 0065-230X, E-ISSN 2162-5557, Vol. 80, 1-38 p.Article in journal (Refereed) Published
Abstract [en]

Platelet-derived growth factor (PDGF) is a family of dimeric isoforms that stimulates, e.g., growth, chemotaxis and cell shape changes of various connective tissue cell types and certain other cells. The cellular effects of PDGF isoforms are exerted through binding to two structurally related tyrosine kinase receptors. Ligand binding induces receptor dimerization and autophosphorylation. This enables a number of SH2 domain containing signal transduction molecules to bind to the receptors, thereby initiating various signaling pathways. PDGF isoforms have important roles during the embryonic development, particularly in the formation of connective tissue in various organs. In the adult, PDGF stimulates wound healing. Overactivity of PDGF has been implicated in certain disorders, including fibrotic conditions, atherosclerosis, and malignancies. Different kinds of PDGF antagonists are currently being developed and evaluated in different animal disease models, as well as in clinical trials.

Place, publisher, year, edition, pages
2001. Vol. 80, 1-38 p.
Keyword [en]
Animals, Arteriosclerosis/drug therapy/metabolism, Fibrosis/drug therapy/metabolism, Glomerulonephritis/drug therapy/metabolism, Humans, Lung Diseases/drug therapy/metabolism, Neoplasms/drug therapy/metabolism, Platelet-Derived Growth Factor/*antagonists & inhibitors/chemistry/*metabolism, Protein Structure; Tertiary, Receptors; Platelet-Derived Growth Factor/chemistry/metabolism, Signal Transduction
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:uu:diva-73368DOI: 10.1016/S0065-230X(01)80010-5PubMedID: 11034538OAI: oai:DiVA.org:uu-73368DiVA: diva2:101278
Available from: 2005-06-02 Created: 2005-06-02 Last updated: 2017-12-14Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMedhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=11034538&dopt=Citation

Authority records BETA

Heldin, Carl-Henrik

Search in DiVA

By author/editor
Heldin, Carl-Henrik
By organisation
Ludwig Institute for Cancer Research
In the same journal
Advances in Cancer Research
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 509 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf